Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Mutational Burden before and after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML)

Aziz Nazha, MD, Betty K. Hamilton, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MDMS, Rabi Hanna, MD, Cassandra M. Hirsch, BS, Teodora Kuzmanovic, BA, Karam Al-Issa, MD, Bartlomiej P. Przychodzen, MSc, Ronald Sobecks, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 3272.

https://doi.org/10.1182/blood.V130.Suppl_1.3272.3272

Published: 2017

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Eric Padron, MD, Yazan F. Madanat, MD, Teodora Kuzmanovic, BA, Nour Abuhadra, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Alan F. List, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 160.

https://doi.org/10.1182/blood.V130.Suppl_1.160.160

Published: 2017

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML)

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Karam Al-Issa, MD, Ahed Makhoul, MD, Vera Adema, PhD, Cassandra M. Hirsch, BS, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Matt Kalaycio, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 1408.

https://doi.org/10.1182/blood.V130.Suppl_1.1408.1408

Published: 2017

Journal Articles

Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Karam Al-Issa, MD, Ahed Makhoul, MD, Vera Adema, PhD, Cassandra M. Hirsch, BS, Anjali S. Advani, MD, Bartlomiej P. Przychodzen, MSc, Teodora Kuzmanovic, BA, Babal K Jha, PhD, Aaron T. Gerds, MDMS, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Matt Kalaycio, MD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 1409.

https://doi.org/10.1182/blood.V130.Suppl_1.1409.1409

Published: 2017

Journal Articles

BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes

Nour Abuhadra, MD, Karam Al-Issa, MD, Sudipto Mukherjee, MD PhD MPH, Cassandra M. Hirsch, BS, Aaron T. Gerds, MDMS, Babal K Jha, PhD, Vera Adema, PhD, Hassan Awada, MD, Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Anjali S. Advani, MD, Yasunobu Nagata, MD PhD, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 5304.

https://doi.org/10.1182/blood.V130.Suppl_1.5304.5304

Published: 2017

Journal Articles

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Tomas Radivoyevitch, PhD, Aziz Nazha, MD, Yazeed Sawalha, MD, Karam Al-Issa, MD, Nour Abuhadra, MD, Teodora Kuzmanovic, BA, Bartlomiej Przychodzen, Cassandra M. Hirsch, BS, Bhumika J. Patel, MD, David Seastone, PhDDO, Yogenthiran Saunthararajah, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 424.

https://doi.org/10.1182/blood.V130.Suppl_1.424.424

Published: 2017

Journal Articles

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Yazan F. Madanat, MD, Mikkael A. Sekeres, MD MS, Karam Al-Issa, MD, Cassandra M. Hirsch, BS, Sudipto Mukherjee, MD PhD MPH, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Babal K Jha, PhD, Vera Adema, PhD, Anjali S. Advani, MD, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 4245.

https://doi.org/10.1182/blood.V130.Suppl_1.4245.4245

Published: 2017

Journal Articles

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

Karam Al-Issa, MD, Yazan F. Madanat, MD, Sudipto Mukherjee, MD PhD MPH, Cassandra M. Hirsch, BS, Aaron T. Gerds, MDMS, Nour Abuhadra, MD, Ahed Makhoul, MD, Hassan Awada, MD, Mohammad Fahad B Asad, MD MBBS, Abhinav Goyal, MD, Anjali S. Advani, MD, Teodora Kuzmanovic, BA, Bartlomiej P. Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2017) 130 (Supplement 1): 2972.

https://doi.org/10.1182/blood.V130.Suppl_1.2972.2972

Published: 2017

Journal Articles

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P. Przychodzen, MSc, Cassandra M. Hirsch, BS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Benjamin L. Ebert, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 157.

https://doi.org/10.1182/blood.V130.Suppl_1.157.157

Published: 2017

Journal Articles

Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group

Aziz Nazha, MD, Mrinal M. Patnaik, MDMBBS, Rami S. Komrokji, MD, Karam Al-Issa, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Alan F. List, MD, Michael R. Savona, MD, Raphael Itzykson, MD PhD, Pierre Fenaux, MD PhD, Valeria Santini, MD, Ayalew Tefferi, MD, Mikkael A. Sekeres, MD MS, Eric Padron, MD

Blood (2017) 130 (Supplement 1): 4255.

https://doi.org/10.1182/blood.V130.Suppl_1.4255.4255

Published: 2017

Journal Articles

BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes

Nour Abuhadra, MD, Karam Al-Issa, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD, PhD, M.P.H., Bhumika Patel, MD, Michael J. Clemente, M.S., Vera Adema, PhD, Cassandra M. Hirsch, BSc, Anjali S. Advani, MD, Mai Aly, Przychodzen P Bartlomiej, Hetty E. Carraway, MD, Jaroslaw P Maciejewski, MD PhD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2016) 128 (22): 4293.

https://doi.org/10.1182/blood.V128.22.4293.4293

Published: 2016

Journal Articles

TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS)

Karam Al-Issa, MD, Mikkael A. Sekeres, MD MS, Alek d Nielsen, B.S., Babal Jha, PhD, Bartlomiej P Przychodzen, MSc, Mai Aly, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Bhumika Patel, MD, Michael J. Clemente, M.S., Sudipto Mukherjee, MD, PhD, M.P.H., Aaron T. Gerds, MD MS, Jaroslaw P Maciejewski, MD PhD FACP, Aziz Nazha, MD

Blood (2016) 128 (22): 4336.

https://doi.org/10.1182/blood.V128.22.4336.4336

Published: 2016

Journal Articles

Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best

Karam Al-Issa, MD, Ahmad Zarzour, MD, Tomas Radivoyevitch, PhD, Matt Kalaycio, MD, Betty K. Hamilton, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD, PhD, M.P.H., Vera Adema, PhD, Michael J. Clemente, M.S., Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Anjali S. Advani, MD, Bartlomiej P Przychodzen, MSc, Hetty E. Carraway, MD MBA, Jaroslaw P Maciejewski, MD PhD FACP, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2016) 128 (22): 50.

https://doi.org/10.1182/blood.V128.22.50.50

Published: 2016

Journal Articles

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P Przychodzen, MSc, Matt Kalaycio, MD, Michael J. Clemente, M.S., Cassandra M. Hirsch, BSc, Benjamin L Ebert, MD PhD, Jaroslaw P. Maciejewski

Blood (2016) 128 (22): 3193.

https://doi.org/10.1182/blood.V128.22.3193.3193

Published: 2016

Journal Articles

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Jing Ai, MD PhD, Valeria Visconte, PhD, Ali Tabarroki, MD, Ahmad Zarzour, MD, Christopher Gerace, Karam Al-Issa, MD, Evan Hsi, Yasmine Hirbawi, Betty K. Hamilton, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Ramon V. Tiu, MD

Blood (2014) 124 (21): 3194.

https://doi.org/10.1182/blood.V124.21.3194.3194

Published: 2014

Journal Articles

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Valeria Visconte, PhD, Ali Tabarroki, MD, Christopher Gerace, Karam Al-Issa, MD, Eric D. Hsi, MD, Heesun J. Rogers, MD PhD, Mikkael A. Sekeres, MD MS, Bernard J. Silver, MD, Alan E. Lichtin, MD, Sudipto Mukherjee, MD MPH, Ramon V. Tiu, MD

Blood (2014) 124 (21): 5597.

https://doi.org/10.1182/blood.V124.21.5597.5597

Published: 2014

NARROW

Mutational Burden before and after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Myeloid Leukemia (AML)

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML)

Patterns of Genomic Associations Can Define Acute Myeloid Leukemia (AML) Phenotype

BCOR Mutations in Myelodysplastic Syndromes (MDS): Mutation Characteristics Impact Clinical Outcomes

Mutational Signatures Associated with Intensity and Duration of Smoking in Myelodysplastic Syndromes (MDS)

Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)

Model Heterogeneity in Predicting Outcomes of Patients with Myelodysplastic Syndromes (MDS)

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group

BCOR and BCORL1 mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes

TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS)

Incorporation of Molecular Data into the Current Prognostic Models in Treated Patients with Myelodysplastic Syndromes: Which Model Is the Best

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes

Impact of Non- JAK2 Molecular Mutations and Cryptic SNP Lesions in Myelofibrosis Patients Treated with Ruxolitinib

Somatic Mutations in Splicing Factor 3b, Subunit 1 (SF3B1) Are a Useful Biomarker to Differentiate Between Clonal and Non-Clonal Causes of Sideroblastic Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only